Golden has been acquired by ComplyAdvantage.Read about it here ⟶

‌

US Patent 10316002 Kinase inhibitors for the treatment of disease

Patent 10316002 was granted and assigned to Dana-Farber Cancer Institute on June, 2019 by the United States Patent and Trademark Office.

Overview Structured Data Issues Contributors Activity

Is a

0

Patent attributes

Patent Applicant

0

Current Assignee

0

Patent Jurisdiction

United States Patent and Trademark Office

0

Patent Number

Patent Inventor Names

Hwan Geun Choi0

Li Tan0

Nathanael Gray0

Date of Patent

June 11, 2019

0

Patent Application Number

156963090

Date Filed

September 6, 2017

0

Patent Citations Received

US Patent 12071432 Phenylaminopyrimidine amide autophagy inhibitors and methods of use thereof

0

US Patent 11518758 Heteroarylaminopyrimidine amide autophagy inhibitors and methods of use thereof

US Patent 11530206 Phenylaminopyrimidine amide autophagy inhibitors and methods of use thereof

US Patent 10906878 Kinase inhibitors for the treatment of disease

US Patent 11590134 Aminopyrimidine amide autophagy inhibitors and methods of use thereof

US Patent 11390611 Heteroarylaminopyrimidine amide autophagy inhibitors and methods of use thereof

Patent Primary Examiner

Alexander R Pagano

0

Patent abstract

The invention relates to compounds and their use in the treatment of disease. Novel irreversible inhibitors of wild-type and mutant forms of EGFR, FGFR, ALK, ROS, JAK, BTK, BLK, ITK, TEC, and/or TXK and their use for the treatment of cell proliferation disorders are described.

Timeline

No Timeline data yet.

Further Resources

Title

Author

Link

Type

Date

No Further Resources data yet.

References

Find more entities like US Patent 10316002 Kinase inhibitors for the treatment of disease

Use the Golden Query Tool to find similar entities by any field in the Knowledge Graph, including industry, location, and more.

Open Query Tool

Golden Query Tool